top of page
Laxxon’s internal pipeline includes reformulating generic drugs for novel therapeutic applications, with intellectual property secured via technology transfer.
![Laxxon - [screen printing (white)].png](https://static.wixstatic.com/media/7a2e6b_7f598b48393c4b0e830f42edb0fb615d~mv2.png/v1/fill/w_100,h_62,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/7a2e6b_7f598b48393c4b0e830f42edb0fb615d~mv2.png)
Product Pipeline
Product
Indication
2025
2026
2027
2028
2029
LXM.1
Epilepsy
LXM.2
Diabetes / Metabolic Syndrome
LXM.4
Rheumatoid Arthritis
LXM.5
Parkinson's Disease
LXM.6
Renal Cell Carcinoma
LXM.10
Thromboembolism
LXM.12
Prostate Carcinoma
LXM.13
Attention-Deficit/
Hyperactivity Disorder
Key:
Formulation & Product Development
Pre-Clinical
Clinical & Registration
(based on bioequivalence studies)
bottom of page